A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice

drug protocol number

NN8640-451

drug sponsor

NovoNordisk

drug study

Sogroya®

drug trial site

My Clinic (Jeddah),King Fahad Medical City (Riyadh),Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh)

drug status

Ongoing

drug phase